Document is current
Any future updates will be listed below
-
Authors
Odetola, Oluwatobi https://orcid.org/0000-0002-2062-1678
Ma, Shuo
- License Information
-
More Information
Article History
Accepted: 22 May 2023
First Online: 6 June 2023
Compliance with Ethical Standards
:
: Oluwatobi Odetola declares that he has no conflict of interest. Shuo Ma has received institutional research funding from AbbVie, Acerta, BeiGene, Gilead, Incyte, Juno, NCCN, Novartis, Pharmacyclics, and TG Therapeutics and has served on advisory boards and delivered lectures for AbbVie, AstraZeneca, Genentech, Gilead, Kite, Janssen, and Pharmacyclics.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
